Povetacicept clinical trials
Also written ALPN-303.
How each study uses povetacicept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the povetacicept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Vertex Pharmaceuticals Incorporated (5) · Alpine Immune Sciences, Inc. (2) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (2)
Studies
Open first, then newest update. How each study uses povetacicept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)RecruitingPhase 2/3Vertex Pharmaceuticals IncorporatedNCT07204275Written as Povetacicept
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeNot yet recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT07890909Written as Povetacicept
- A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyEnrolling by invitationPhase 3Vertex Pharmaceuticals IncorporatedNCT07807995Written as Povetacicept
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisActive, not recruitingPhase 2Vertex Pharmaceuticals IncorporatedNCT07501702Written as Povetacicept
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingPhase 1/2Alpine Immune Sciences, Inc.NCT05732402Written as Povetacicept
- An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedPhase 1/2Alpine Immune Sciences Inc, A Subsidiary of VertexNCT05757570Written as Povetacicept
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Active, not recruitingPhase 3Alpine Immune Sciences Inc, A Subsidiary of VertexNCT06564142Written as Povetacicept
- A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept PresentationsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT07010406Written as Povetacicept
- A Study of ALPN-303 in Adult Healthy VolunteersCompletedPhase 1Alpine Immune Sciences, Inc.NCT05034484Written as ALPN-303
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call povetacicept · ClinicalTrials.gg INT016470
- UNII (FDA) EN2U82XV65POVETACICEPTOne source FDA
- NCI Thesaurus C190436PovetaciceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EN2U82XV65 | POVETACICEPT | One source FDA |
| NCI Thesaurus | C190436 | Povetacicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.